• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

《Lugano 分类在霍奇金和非霍奇金淋巴瘤初始评估、分期和疗效评估中的应用:PRoLoG 共识倡议(第 2 部分:技术)》

Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2-Technical).

机构信息

Relay Therapeutics, Cambridge, Massachusetts;

King's College London and Guy's and St. Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, King's Health Partners, London, United Kingdom.

出版信息

J Nucl Med. 2023 Feb;64(2):239-243. doi: 10.2967/jnumed.122.264124. Epub 2022 Jul 14.

DOI:10.2967/jnumed.122.264124
PMID:35835581
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9902846/
Abstract

The aim of this initiative was to provide consensus recommendations from a consortium of academic and industry experts in the field of lymphoma and imaging for the consistent application of imaging assessment with the Lugano classification. Consensus was obtained through a series of meetings from July 2019 to October 2021 sponsored by the PINTaD (Pharma Imaging Network for Therapeutics and Diagnostics) as part of the ProLoG (INTaD espnse criteria in ymphoma wrking roup) consensus initiative. Consensus recommendations encompass all technical imaging aspects of the Lugano classification. Some technical considerations for PET/CT and diagnostic CT are clarified with regards to required imaging series and scan visits, as well as acquisition and reconstruction of PET images and influence of lesion size and background activity. Recommendations are given on the role of imaging and clinical reviewers as well as on training and monitoring. Finally, an example template of an imaging case report form is provided to support efficient collection of data with Lugano Classification. Consensus recommendations are made to comprehensively address technical and imaging areas of inconsistency and ambiguity in the classification encountered by end users. Such guidance should be used to support standardized acquisition and evaluation with the Lugano 2014.

摘要

本倡议的目的是为淋巴瘤和影像学领域的学术和行业专家联盟提供共识建议,以一致应用 Lugano 分类进行影像学评估。通过 2019 年 7 月至 2021 年 10 月由 PINTaD(治疗和诊断药物成像网络)赞助的一系列会议,获得了共识,作为 ProLoG(INTaD 淋巴瘤工作组中的反应标准)共识倡议的一部分。共识建议涵盖了 Lugano 分类的所有技术影像学方面。对于 PET/CT 和诊断 CT,一些技术注意事项得到了澄清,涉及到所需的影像学系列和扫描访问,以及 PET 图像的采集和重建,以及病变大小和背景活动的影响。还就影像学和临床审查员的作用以及培训和监测提出了建议。最后,提供了一个影像学病例报告表模板,以支持 Lugano 分类下的数据高效收集。制定了共识建议,以全面解决分类中遇到的技术和影像学不一致和模糊的问题。应使用此类指南来支持 Lugano 2014 的标准化采集和评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b561/9902846/f1603cd9cced/jnumed.122.264124absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b561/9902846/f1603cd9cced/jnumed.122.264124absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b561/9902846/f1603cd9cced/jnumed.122.264124absf1.jpg

相似文献

1
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2-Technical).《Lugano 分类在霍奇金和非霍奇金淋巴瘤初始评估、分期和疗效评估中的应用:PRoLoG 共识倡议(第 2 部分:技术)》
J Nucl Med. 2023 Feb;64(2):239-243. doi: 10.2967/jnumed.122.264124. Epub 2022 Jul 14.
2
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical).《卢加诺分类在霍奇金和非霍奇金淋巴瘤初始评估、分期和疗效评估中的应用:PRoLoG 共识倡议(第 1 部分-临床)》。
J Nucl Med. 2023 Jan;64(1):102-108. doi: 10.2967/jnumed.122.264106. Epub 2022 Jul 14.
3
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.霍奇金淋巴瘤和非霍奇金淋巴瘤初始评估、分期及反应评估的建议:卢加诺分类
J Clin Oncol. 2014 Sep 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800.
4
CT, MRI, and FDG PET/CT in the Assessment of Lymph Node Involvement in Pediatric Hodgkin Lymphoma: An Expert Consensus Definition by an International Collaboration on Staging Evaluation and Response Criteria Harmonization for Children, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL).CT、MRI及FDG PET/CT在儿童霍奇金淋巴瘤淋巴结受累评估中的应用:儿童、青少年和青年霍奇金淋巴瘤分期评估与反应标准协调国际协作组(SEARCH for CAYAHL)的专家共识定义
Radiology. 2025 Jan;314(1):e232650. doi: 10.1148/radiol.232650.
5
F-FDG PET/CT in the clinical management of patients with lymphoma.18F-氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描在淋巴瘤患者临床管理中的应用
Rev Esp Med Nucl Imagen Mol. 2017 Sep-Oct;36(5):312-321. doi: 10.1016/j.remn.2017.03.004. Epub 2017 May 5.
6
Revised staging system for malignant lymphoma based on the Lugano classification.基于卢加诺分类的恶性淋巴瘤修订分期系统。
Jpn J Clin Oncol. 2019 Oct 1;49(10):895-900. doi: 10.1093/jjco/hyz111.
7
Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.正电子发射断层扫描/计算机断层扫描在霍奇金和 B 细胞非霍奇金淋巴瘤治疗中的应用:更新。
Cancer. 2021 Oct 15;127(20):3727-3741. doi: 10.1002/cncr.33772. Epub 2021 Jul 19.
8
[Staging and Treatment Response Evaluation in Malignant Lymphomas - Czech Lymphoma Study Group Recommendations According to Criteria Revised in 2014 (Lugano Classification)].[恶性淋巴瘤的分期及治疗反应评估——捷克淋巴瘤研究组根据2014年修订标准(卢加诺分类)提出的建议]
Klin Onkol. 2016;29(4):295-302. doi: 10.14735/amko2016295.
9
Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.霍奇金淋巴瘤和非霍奇金淋巴瘤的诊断、分期和反应评估的影像学。
Pediatr Radiol. 2019 Oct;49(11):1545-1564. doi: 10.1007/s00247-019-04529-8. Epub 2019 Oct 16.
10
Imaging for Staging and Response Assessment in Lymphoma.淋巴瘤的分期和疗效评估影像学。
Radiology. 2015 Aug;276(2):323-38. doi: 10.1148/radiol.2015142088.

引用本文的文献

1
Automated Lugano Metabolic Response Assessment in F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on F-Fluorodeoxyglucose-Positron Emission Tomography.基于 F-氟脱氧葡萄糖正电子发射断层扫描的深度学习在 F-氟脱氧葡萄糖- 正电子发射断层显像中代谢反应评估的自动分析在 F-氟脱氧葡萄糖- 正电子发射断层显像中代谢反应评估的自动分析在 F-氟脱氧葡萄糖- 正电子发射断层显像中代谢反应评估的自动分析在 F-氟脱氧葡萄糖- 正电子发射断层显像中代谢反应评估的自动分析
J Clin Oncol. 2024 Sep 1;42(25):2966-2977. doi: 10.1200/JCO.23.01978. Epub 2024 Jun 6.
2
[Efficacy and safety of bendamustine-rituximab combination therapy for newly diagnosed indolent B-cell non-Hodgkin's lymphoma and elderly mantle cell lymphoma: a multi-center prospective phase II clinical trial in China].苯达莫司汀-利妥昔单抗联合治疗新诊断的惰性B细胞非霍奇金淋巴瘤和老年套细胞淋巴瘤的疗效及安全性:一项中国多中心前瞻性II期临床试验
Zhonghua Xue Ye Xue Za Zhi. 2023 Jul 14;44(7):550-554. doi: 10.3760/cma.j.issn.0253-2727.2023.07.004.
3

本文引用的文献

1
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical).《卢加诺分类在霍奇金和非霍奇金淋巴瘤初始评估、分期和疗效评估中的应用:PRoLoG 共识倡议(第 1 部分-临床)》。
J Nucl Med. 2023 Jan;64(1):102-108. doi: 10.2967/jnumed.122.264106. Epub 2022 Jul 14.
2
Radiologists and Clinical Trials: Part 2: Practical Statistical Methods for Understanding and Monitoring Independent Reader Performance.放射科医生与临床试验(二):理解和监测独立读片者表现的实用统计学方法
Ther Innov Regul Sci. 2021 Nov;55(6):1122-1138. doi: 10.1007/s43441-021-00317-5. Epub 2021 Jul 9.
3
The role of clinical imaging in oncology drug development: progress and new challenges.临床影像学在肿瘤药物研发中的作用:进展与新挑战。
Br J Radiol. 2023 Oct;96(1150):20211126. doi: 10.1259/bjr.20211126. Epub 2023 Aug 15.
4
Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma.淋巴瘤中的代谢重编程及潜在治疗靶点
Int J Mol Sci. 2023 Mar 13;24(6):5493. doi: 10.3390/ijms24065493.
5
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical).《卢加诺分类在霍奇金和非霍奇金淋巴瘤初始评估、分期和疗效评估中的应用:PRoLoG 共识倡议(第 1 部分-临床)》。
J Nucl Med. 2023 Jan;64(1):102-108. doi: 10.2967/jnumed.122.264106. Epub 2022 Jul 14.
Radiologists and Clinical Trials: Part 1 The Truth About Reader Disagreements.
放射科医生和临床试验:第 1 部分 关于读片分歧的真相。
Ther Innov Regul Sci. 2021 Nov;55(6):1111-1121. doi: 10.1007/s43441-021-00316-6. Epub 2021 Jul 6.
4
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients.弥漫性大 B 细胞淋巴瘤中 PET 中期评估的最佳时机和标准:一项 1692 例患者的对比研究。
Blood Adv. 2021 May 11;5(9):2375-2384. doi: 10.1182/bloodadvances.2021004467.
5
Interim PET in Diffuse Large B-Cell Lymphoma.弥漫性大 B 细胞淋巴瘤的中期 PET。
J Nucl Med. 2021 Aug 1;62(8):1068-1074. doi: 10.2967/jnumed.120.255034. Epub 2020 Nov 27.
6
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.奥滨尤妥珠单抗对比利妥昔单抗用于晚期弥漫性大 B 细胞淋巴瘤:LYSA 的一项基于 PET 指导的随机 3 期研究。
Blood. 2021 Apr 29;137(17):2307-2320. doi: 10.1182/blood.2020008750.
7
Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUV Method.弥漫性大 B 细胞淋巴瘤的临时 PET 评估:采用已发布的推荐标准比较 Deauville 5 分法和 SUVΔ 值法。
J Nucl Med. 2021 Jan;62(1):37-42. doi: 10.2967/jnumed.120.244145. Epub 2020 May 8.
8
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.弥漫性大 B 细胞淋巴瘤中中间 FDG-PET 的预后价值:CALGB 50303 临床试验结果。
Blood. 2020 Jun 18;135(25):2224-2234. doi: 10.1182/blood.2019003277.
9
The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy.作为一种用于测量癌症治疗反应的成像生物标志物的 FDG PET/CT 的 QIBA 特征。
Radiology. 2020 Mar;294(3):647-657. doi: 10.1148/radiol.2019191882. Epub 2020 Jan 7.
10
Metabolic Tumor Volume Metrics in Lymphoma.淋巴瘤的代谢肿瘤体积指标。
Semin Nucl Med. 2018 Jan;48(1):50-66. doi: 10.1053/j.semnuclmed.2017.09.005.